According to a newly published market research report by 24LifeSciences, Global Lenvatinib Mesylate Capsules Market was valued at USD 1.3 billion in 2024 and is projected to reach USD 2.2 billion by 2032, growing at a compound annual growth rate (CAGR) of 6.8% during the forecast period 20252032. Lenvatinib Mesylate, commercially known as Lenvima, is a multi-kinase inhibitor specifically...

The global imatinib drug market continues to play a crucial role in the oncology sector due to the widespread use of imatinib in targeted cancer therapies. As one of the pioneering tyrosine kinase inhibitors, imatinib has significantly transformed the treatment landscape for specific cancers by offering targeted therapeutic benefits. The drug remains an important treatment option in various...